| 001 | 271966 | ||
| 005 | 20240918164039.0 | ||
| 024 | 7 | _ | |a 10.1093/neuonc/noae071 |2 doi |
| 024 | 7 | _ | |a pmid:38578306 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC11376455 |2 pmc |
| 024 | 7 | _ | |a 1522-8517 |2 ISSN |
| 024 | 7 | _ | |a 1523-5866 |2 ISSN |
| 037 | _ | _ | |a DZNE-2024-01108 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Obrecht-Sturm, Denise |0 0000-0002-3216-8452 |b 0 |
| 245 | _ | _ | |a Treatment response as surrogate to predict risk for disease progression in pediatric medulloblastoma with persistent magnetic resonance imaging lesions after first-line treatment. |
| 260 | _ | _ | |a Oxford |c 2024 |b Oxford Univ. Press |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1726649767_21997 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a This study aims at clarifying the impact of persistent residual lesions following first-line treatment for pediatric medulloblastoma.Data on 84 pediatric patients with medulloblastoma and persistent residual lesions on centrally reviewed magnetic resonance imaging (MRI) at the end of first-line therapy were analyzed.Twenty patients (23.8%) had residual lesions in the tumor bed (R+/M0), 51 (60.7%) had distant lesions (R0/M+) and 13 (15.5%) had both (R+/M+). Overall response to first-line therapy was minor or partial (≥ 25% reduction, minor response [MR]/PR) for 64 (76.2%) and stable disease (SD) for 20 patients (23.8%). Five-year post-primary-treatment progression-free (pptPFS) and overall survival (pptOS) were superior after MR/PR (pptPFS: 62.5 ± 7.0%[MR/PR] vs. 35.9 ± 12.8%[SD], P = .03; pptOS: 79.7 ± 5.9[MR/PR] vs. 55.5 ± 13.9[SD], P = .04). Furthermore, R+/M + was associated with a higher risk for progression (5-year pptPFS: 22.9 ± 17.9%[R+, M+] vs. 72.4 ± 12.0%[R+, M0]; P = .03). Watch-and-wait was pursued in 58 patients, while n = 26 received additional treatments (chemotherapy only, n = 19; surgery only, n = 2; combined, n = 3; valproic acid, n = 2), and their outcomes were not superior to watch-and-wait (5-year pptPFS: 58.5 ± 7.7% vs. 51.6 ± 10.7% P = .71; 5-year pptOS: 76.3 ± 6.9% vs. 69.8 ± 9.7%, P = .74). For the whole cohort, 5-year pptPFS by molecular subgroup (58 cases) were WNT: 100%, SHH: 50.0 ± 35.4%, group-4, 52.5 ± 10.5, group-3 54.2 ± 13.8%; (P = .08).Overall response and extent of lesions can function as surrogate parameters to predict outcomes in pediatric MB patients with persistent lesions after first-line therapy. Especially in the case of solitary persistent medulloblastoma MRI lesions, additional therapy was not beneficial. Therefore, treatment response, extent/kind of residual lesions and further diagnostic information need consideration for indication of additional treatments for persisting lesions. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a MRI |2 Other |
| 650 | _ | 7 | |a children |2 Other |
| 650 | _ | 7 | |a medulloblastoma |2 Other |
| 650 | _ | 7 | |a persistent residual disease |2 Other |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Medulloblastoma: diagnostic imaging |2 MeSH |
| 650 | _ | 2 | |a Medulloblastoma: pathology |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Child |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Magnetic Resonance Imaging: methods |2 MeSH |
| 650 | _ | 2 | |a Cerebellar Neoplasms: diagnostic imaging |2 MeSH |
| 650 | _ | 2 | |a Cerebellar Neoplasms: pathology |2 MeSH |
| 650 | _ | 2 | |a Disease Progression |2 MeSH |
| 650 | _ | 2 | |a Child, Preschool |2 MeSH |
| 650 | _ | 2 | |a Adolescent |2 MeSH |
| 650 | _ | 2 | |a Follow-Up Studies |2 MeSH |
| 650 | _ | 2 | |a Prognosis |2 MeSH |
| 650 | _ | 2 | |a Retrospective Studies |2 MeSH |
| 650 | _ | 2 | |a Survival Rate |2 MeSH |
| 650 | _ | 2 | |a Infant |2 MeSH |
| 650 | _ | 2 | |a Neoplasm, Residual: diagnostic imaging |2 MeSH |
| 650 | _ | 2 | |a Neoplasm, Residual: pathology |2 MeSH |
| 700 | 1 | _ | |a Schömig, Lena |b 1 |
| 700 | 1 | _ | |a Mynarek, Martin |0 0000-0003-3302-2719 |b 2 |
| 700 | 1 | _ | |a Bison, Brigitte |b 3 |
| 700 | 1 | _ | |a Schwarz, Rudolf |b 4 |
| 700 | 1 | _ | |a Pietsch, Torsten |0 P:(DE-2719)2812617 |b 5 |u dzne |
| 700 | 1 | _ | |a Pfister, Stefan M |0 0000-0002-5447-5322 |b 6 |
| 700 | 1 | _ | |a Sill, Martin |b 7 |
| 700 | 1 | _ | |a Sturm, Dominik |b 8 |
| 700 | 1 | _ | |a Sahm, Felix |0 0000-0001-5441-1962 |b 9 |
| 700 | 1 | _ | |a Kortmann, Rolf-Dieter |b 10 |
| 700 | 1 | _ | |a Gerber, Nicolas U |b 11 |
| 700 | 1 | _ | |a von Bueren, André O |b 12 |
| 700 | 1 | _ | |a Fleischhack, Gudrun |b 13 |
| 700 | 1 | _ | |a Schüller, Ulrich |0 P:(DE-2719)9000979 |b 14 |
| 700 | 1 | _ | |a Nussbaumer, Gunther |b 15 |
| 700 | 1 | _ | |a Benesch, Martin |b 16 |
| 700 | 1 | _ | |a Rutkowski, Stefan |b 17 |
| 773 | _ | _ | |a 10.1093/neuonc/noae071 |g Vol. 26, no. 9, p. 1712 - 1722 |0 PERI:(DE-600)2094060-9 |n 9 |p 1712 - 1722 |t Neuro-Oncology |v 26 |y 2024 |x 1522-8517 |
| 856 | 4 | _ | |u https://pub.dzne.de/record/271966/files/DZNE-2024-01108%20SUP.zip |
| 856 | 4 | _ | |u https://pub.dzne.de/record/271966/files/DZNE-2024-01108_Restricted.pdf |
| 856 | 4 | _ | |u https://pub.dzne.de/record/271966/files/DZNE-2024-01108_Restricted.pdf?subformat=pdfa |x pdfa |
| 909 | C | O | |o oai:pub.dzne.de:271966 |p VDB |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 5 |6 P:(DE-2719)2812617 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2023-10-24 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NEURO-ONCOLOGY : 2022 |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-24 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-10-24 |
| 915 | _ | _ | |a IF >= 15 |0 StatID:(DE-HGF)9915 |2 StatID |b NEURO-ONCOLOGY : 2022 |d 2023-10-24 |
| 920 | 1 | _ | |0 I:(DE-2719)1011009 |k Brainbank (Bonn) |l Brainbank Unit Bonn |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-2719)1011009 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::